# NCT02513186 (NCT02513186)

> Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02513186
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Sanofi
- Conditions: Plasma Cell Myeloma
- Interventions: lenalidomide; bortezomib; cyclophosphamide; dexamethasone; isatuximab SAR650984
- Enrollment: 90
- Primary outcome: Assessment of dose-limiting toxicities (DLTs) in VCDI cohort
- Primary outcome: Overall response rate (VCDI)
- Primary outcome: Complete response rate (VCDI)
- Primary outcome: Complete response rate (VRDI)

## Commentary we found

- X threads: 7
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02513186

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02513186", "email": "<work email>"}; the inbox owner confirms by the emailed link.